CSF2 and neoplasm: The potential for GM-CSF to stimulate immune responses has been shown in many tumor models, including a murine melanoma in which transgenic expression of GM-CSF provided protection to subsequent tumor challenge in over 90% of the animals [142], and promising results have been observed in other tumors when used alone and in combination with other immunomodulators such as checkpoint-blocking antibodies [143,144].